LEADER 01554nam  2200493 a 450 
001 9910818143903321
005 20240313135304.0
010   $a1-118-35459-1
010   $a1-118-35458-3
010   $a1-299-24195-6
010   $a1-118-35457-5
035   $a(OCoLC)828793860
035   $a(MiAaPQ)EBC1119446
035   $a(Au-PeEL)EBL1119446
035   $a(CaPaEBR)ebr10662566
035   $a(CaONFJC)MIL455445
035   $a(CKB)2560000000098192
035   $a(EXLCZ)992560000000098192
100   $a20121002d2013      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aFusion protein technologies for biopharmaceuticals $eapplications and challenges /$fedited by Stefan R. Schmidt
205   $a1st ed.
210   $aHoboken, N.J. $cJ. Wiley & Sons$dc2013
215   $a1 online resource (654 p.)
311   $a0-470-64627-6 
320   $aIncludes bibliographical references and index.
327   $apt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
606   $aRecombinant proteins
606   $aBiopharmaceutics
615  0$aRecombinant proteins.
615  0$aBiopharmaceutics.
676   $a615.7
701   $aSchmidt$b Stefan R$0174542
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910818143903321
996   $aFusion protein technologies for biopharmaceuticals$93938464
997   $aUNINA